Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cancer Clinical Decision Tools Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The cancer clinical decision tools market has seen significant expansion in recent years. It is projected to increase from $0.55 billion in 2025 to $0.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.0%. The growth observed in the past can be attributed to several factors, including rising cancer incidence rates, an increasing workload on primary care physicians, the scarcity of early diagnostic tools within primary care, a heightened focus on referral accuracy, and the expansion of hospital and clinic infrastructure.
The cancer clinical decision tools market is projected to experience significant expansion over the next few years, with its size anticipated to reach $0.88 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 10.2%. This expected growth during the forecast period is attributable to the progress of AI-driven decision tools, the integration of genomic and risk profiling data, the expansion of digital health platforms, increasing government screening initiatives, and the growing adoption of evidence-based oncology guidelines. Key trends for this period include a rising adoption of clinical decision support tools in oncology, an intensified focus on early cancer detection and risk stratification, increased use of symptom checkers and risk calculators by GPs, the expansion of guideline-based referral and decision frameworks, and the integration of cancer decision tools into primary care workflows.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Clinical Decision Tools Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
An anticipated increase in cancer cases is projected to drive expansion within the cancer clinical decision tools market in the coming period. Cancer incidence refers to the quantity of newly diagnosed cancer cases within a defined population over a specific duration, indicating the frequency of the disease’s occurrence. The occurrence of cancer is increasing, attributed to greater exposure to risk factors like unhealthy lifestyles, which can result in genetic mutations and irregular cell development progressively. These cancer clinical decision tools facilitate more effective tracking, prediction, and management of cancer cases, allowing for early detection and prompt intervention that can impact discernible cancer incidence trends. As an illustration, in October 2025, data from the NHS England, a UK-based publicly funded healthcare system, revealed 354,820 new cancer diagnoses in 2023, representing an increase of 8,605 compared to 2022. Consequently, the worldwide escalation in cancer incidence rates is set to heighten the demand for the cancer clinical decision tools market.
Cancer Clinical Decision Tools Market Segmentation And Category Overview
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
Subsegments:
1) By Risk Assessment Tool (RAT): Family History Assessment, Genetic Testing and Counseling, Lifestyle and Environmental Risk Factors Evaluation
2) By Qcancer: Symptom Checker, Risk Calculator, Guideline-Based Recommendations
Cancer Clinical Decision Tools Market Innovation Trends Shaping Future Development
Leading firms within the cancer clinical decision tools sector are progressively adopting AI-driven prognostic support systems. This adoption is driven by the growing requirement for individualized, data-centric oncology care, fueled by increasing cancer rates, the necessity for improved risk assessment, and the push to refine treatment protocols. Such AI prognostic technologies employ deep-learning algorithms to examine diverse data sources, including medical imaging, electronic health records, and biological markers, enabling more accurate predictions of patient outcomes such as survival rates, risk of recurrence, or responsiveness to therapy, outperforming older rule-based methods. A pertinent example is Onc.AI, a health-tech company based in the US, which announced in February 2025 that its Serial CTRS (Cancer Treatment Risk Stratification) tool received FDA Breakthrough Device Designation. This specific AI instrument categorizes non–small cell lung cancer (NSCLC) patients into groups with high or low mortality risk by utilizing a deep-learning algorithm to analyze diagnostic imaging scans, thereby assisting oncologists in making better-informed choices regarding treatment aggression and subsequent monitoring. The capability of Serial CTRS to forecast long-term survival significantly improves patient categorization, facilitates more customized treatment strategies, and optimizes the distribution of resources, marking a substantial advancement compared to conventional prognostic approaches that depend on a restricted set of clinical indicators.
Cancer Clinical Decision Tools Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the cancer clinical decision tools market are McKesson Corporation, Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc.
View The Full Cancer Clinical Decision Tools Market Report:
Cancer Clinical Decision Tools Market Largest Region By Revenue And Market Share
North America was the largest region in the cancer clinical decision tools market in 2025. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
